Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Endocare, Inc.
Genrix grossed $478.9m in the largest initial public offering from an innovative drug-focused biotech on Shanghai's STAR Market since February 2022. Meanwhile, Laekna and Cutia launched two smaller IPOs in Hong Kong.
China continues to dominate the latest list of global billionaires and top execs from domestic pharma firms Hengrui and Hansoh ranked among the wealthiest overall in the country, along with the founder of vaccine maker Zhifei Bio. A number of top Chinese biopharma business executives also featured in the global top 100 billionaires list.
ChromaDex trims loss, adds Nestle as Niagen customer; currency exchange slams Mannatech; Asia-Pacific sales, currency exchange Rock USANA results; and Lannett sees upsides after 25% sales slide.
With the first half of 2022 ending, two Chinese developers of innovative drugs - antibody specialist Chongqing Genrix Biopharmaceutical and Suzhou Teligene, which focuses on small molecules, are looking to go public on Shanghai’s STAR Market, ending a recent drought of biopharma listings.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.